ArticleFrontiers in public health2026
The impact of the consistency evaluation policy of generic drugs on the integration of innovation chain and industrial chain in the pharmaceutical manufacturing industry.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The Consistency Evaluation Policy of Generic Drugs is a major quality-oriented regulatory reform in China's pharmaceutical manufacturing industry. Whether and how this policy facilitates the integration of the innovation chain and the industrial chain at the enterprise level remains insufficiently examined. This study evaluates the policy effect and investigates potential mechanisms. Methods: This study used panel data on A-share listed pharmaceutical enterprises from 2013 to 2023. Enterprises were treated as the micro-level carriers of both the innovation chain and the industrial chain, and a enterprise-level index was constructed to measure their integration. A difference-in-differences (DID) design was employed to estimate the impact of the Consistency Evaluation Policy of Generic Drugs. Mechanism analyses focused on government subsidies and market concentration, and heterogeneity was assessed by market demand and total factor productivity (TFP). Results: The Consistency Evaluation Policy of Generic Drugs significantly promoted the integration of the innovation chain and the industrial chain. Mechanism tests suggested that the effect operated through two channels: increased government subsidies and higher market concentration. The positive effect was stronger among enterprises facing larger market demand. Moreover, the effect was significant for enterprises with higher TFP, while it was not statistically significant for enterprises with lower TFP. Discussion: These findings suggest that policy implementation can be strengthened by (1) improving the depth and precision of the Consistency Evaluation Policy of Generic Drugs, (2) enhancing the targeting of government subsidies and supporting an appropriate degree of industry concentration where warranted, and (3) adopting differentiated guidance to stimulate enterprise vitality through multiple measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.